skip-to-main

Spikevax (previously COVID‑19 Vaccine Moderna)

A Conditional Marketing Authorisation (CMA) has been granted in the EU for the product Spikevax (previously COVID‑19 Vaccine Moderna) to prevent coronavirus disease 2019 (COVID‑19) in people from 12 years of age.

Patient Information Leaflet

Patient Information Leaflet

Summary of Product Characteristics

Summary of Product Characteristics

Storage, Handling, Dosage and Administration

Storage, Handling, Dosage and Administration

2nd Dose Reminder Card

2nd Dose Reminder Card

Contact Moderna

8am-5pm WET – Mon - Fri
EMEAMedinfo@modernatx.com